COLORADO SPRINGS, Colo.,
Nov. 7, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTC: CBIS), a U.S. company
specializing in cannabis formulation-based drug development and
related consulting, is pleased to announce that as disclosed on
August 25, 2014, the Company is in
the final stages for the acquisition of a Marihuana for Medical
Purposes (Canada) company, which has already
submitted application to Health Canada (the "TargetCo"). The
acquisition includes a site located in British Columbia, Canada with a highly
experienced and professional team. The TargetCo currently produces
marijuana under the Marihuana Medical Access Regulations
(Canada). While the Company is
optimistic about the acquisition of the TargetCo, it recognizes
that, as with due diligence and negotiations, the process has been
lengthy and without assurances until the transaction closes.
Raymond Dabney, Director,
President and CEO, notes that "the Company is conducting its last
stages of due diligence and is excited about the opportunity to
expand its operations in Canada
and begin utilizing some of the highest quality cannabis in the
world to research and develop cannabinoid based medicine and
therapies and to commercialize medical cannabis."
The picture below is an actual picture taken of the facility
located in British Columbia. This
is one of several growing rooms located in the facility. Please
click
http://www.cannabisscience.com/news-media/cbis-latest-news/654-cannabis-science-inc-cbis-is-in-the-final-stages-to-acquire-a-british-columbia-company-that-has-submitted-marihuana-for-medical-purposes-application-to-health-canada-as-previously-announced
to see the images of the TargetCo facility.
A double stack of ballasts is required to meet the power demands
for the state of the art lighting system in the growing
facility.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and
neurological conditions.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," "intend," "believe,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc., does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.
Cannabis Science, Inc.
Raymond C. Dabney, President &
CEO
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad Johnson, Esq, Director, COO,
& General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Photo - http://photos.prnewswire.com/prnh/20141107/157365
Photo - http://photos.prnewswire.com/prnh/20141107/157366
SOURCE Cannabis Science, Inc.